Diabetes mellitus with an increased prevalence is expected to affect more than 640 million adults worldwide by the year 2040. The patients with diabetes are often predisposed to a higher risk of adverse outcomes from atherosclerotic cardiovascular disease, heart failure, and renal disease. People with diabetes have a higher risk of heart failure which is independent of coronary disease. However, limited data are available in order to guide treatments for the prevention of heart failure.
Such constellation of diabetes, atherosclerotic cardiovascular disease, and heart failure requires determining of diabetic therapies that are not only safe but also effective in reducing cardiovascular risk. According to a recent study finding published in the New England Journal of Medicine, treatment with dapagliflozin has positive effects on cardiovascular outcomes in T2DM. Patients with Type 2…
